This report contains the first therapeutic results with the multiple combination rifampicin + isoniazid + sulfamethoxazole + trimethoprim in the treatment of malaria. Clinical symptoms declined rapidly and parasites were cleared from the erythrocytes. Tolerance was excellent. This fixed combination is outstandingly practicable, with few problems with compliance.
Following the brief information on a new malaria treatment with the fixed multiple combination Cotrifazid (rifampicin + isoniazid + sulfamethoxazole + trimethoprim) in Chemotherapy [1995;41:396–398], very good results are reported for the treatment of 61 patients with various forms of malaria. The tolerance was found to be good. Some relevant fundamental considerations (chemoresistance, synergism/antagonism, fixed multiple combination, switching from monotherapy to combination therapy) and the implementation of the principle of a ‘multidisease therapy’ are discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.